No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
WGS240719C35000
- 0.65
- 0.000.00%
15min DelayTrading Jul 17 14:07 ET
0.00High0.00Low
0.00Open0.65Pre Close0 Volume63 Open Interest35.00Strike Price0.00Turnover171.21%IV10.06%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.65Extrinsic Value100Contract SizeAmericanOptions Type0.3004Delta0.0965Gamma49.83Leverage Ratio-0.4717Theta0.0004Rho14.97Eff Leverage0.0073Vega
Intraday
- 5D
- Daily
News
What Makes GeneDx Holdings Corp. (WGS) a Strong Momentum Stock: Buy Now?
GeneDx Holdings Price Target Raised to $28.00/Share From $12.50 by Goldman Sachs
GeneDx Holdings Price Target Raised to $28.00/Share From $12.50 by Goldman
Express News | Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $28
Express News | GeneDx Holdings Corp : TD Cowen Raises Target Price to $46 From $24
13D Filings -- Barron's
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
All You Need to Know About GENEDX HOLDINGS (WGS) Rating Upgrade to Strong Buy
Comments
Hello Mooers! ![]()
A quick recap for the month ending April 30, 2024.
![]()
Ten stocks with >300% YTD
![]()
$Swvl Holdings(SWVL.US$718.40%
![]()
$Root Inc(ROOT.US$564.60%
![]()
$Elevation Oncology(ELEV.US$561.08%
![]()
$JanOne(JAN.US$554.05%
![]()
$GeneDx Holdings(WGS.US$520.71%
![]()
$Corbus Pharmaceuticals(CRBP.US$513.25%
![]()
$AGBA Group(AGBA.US$482.90%
![]()
$Janux Therapeutics(JANX.US$431.22%
![]()
$Dave Inc(DAVE.US$4...
A quick recap for the month ending April 30, 2024.
4
1
$GeneDx Holdings(WGS.US$
NEWS
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
NEWS
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
1
The low P/S of GeneDx Holdings indicates investors expect limited future growth. A recent share price boost hasn't shifted investor perceptions. The low P/S is largely because shareholders are pessimistic about revenue prospects.
Read more
Mars MoooOP :